GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (NAS:GMAB) » Definitions » Cyclically Adjusted Price-to-FCF

Genmab A/S (Genmab A/S) Cyclically Adjusted Price-to-FCF : 51.18 (As of Apr. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Cyclically Adjusted Price-to-FCF?

As of today (2024-04-28), Genmab A/S's current share price is $28.15. Genmab A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.55. Genmab A/S's Cyclically Adjusted Price-to-FCF for today is 51.18.

The historical rank and industry rank for Genmab A/S's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

GMAB' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 51.5   Med: 159.58   Max: 914.08
Current: 52.91

During the past years, Genmab A/S's highest Cyclically Adjusted Price-to-FCF was 914.08. The lowest was 51.50. And the median was 159.58.

GMAB's Cyclically Adjusted Price-to-FCF is ranked better than
52.48% of 101 companies
in the Biotechnology industry
Industry Median: 54.65 vs GMAB: 52.91

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Genmab A/S's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $0.356. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.55 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab A/S Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Genmab A/S's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Cyclically Adjusted Price-to-FCF Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 266.01 172.59 139.51 113.69 58.34

Genmab A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 113.69 83.46 82.31 72.33 58.34

Competitive Comparison of Genmab A/S's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Genmab A/S's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Cyclically Adjusted Price-to-FCF falls into.



Genmab A/S Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Genmab A/S's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=28.15/0.55
=51.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Genmab A/S's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.356/116.7000*116.7000
=0.356

Current CPI (Dec. 2023) = 116.7000.

Genmab A/S Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.007 99.600 -0.008
201406 0.015 99.700 0.018
201409 0.008 99.700 0.009
201412 0.002 99.400 0.002
201503 -0.018 100.200 -0.021
201506 -0.030 100.300 -0.035
201509 0.033 100.200 0.038
201512 0.058 99.800 0.068
201603 -0.003 100.200 -0.003
201606 0.051 100.600 0.059
201609 0.050 100.200 0.058
201612 -0.024 100.300 -0.028
201703 0.174 101.200 0.201
201706 0.124 101.200 0.143
201709 0.004 101.800 0.005
201712 0.058 101.300 0.067
201803 0.116 101.700 0.133
201806 0.029 102.300 0.033
201809 -0.050 102.400 -0.057
201812 0.045 102.100 0.051
201903 0.154 102.900 0.175
201906 0.041 102.900 0.046
201909 0.062 102.900 0.070
201912 0.033 102.900 0.037
202003 0.417 103.300 0.471
202006 0.022 103.200 0.025
202009 1.209 103.500 1.363
202012 -0.212 103.400 -0.239
202103 0.281 104.300 0.314
202106 0.068 105.000 0.076
202109 0.089 105.800 0.098
202112 0.040 106.600 0.044
202203 0.119 109.900 0.126
202206 0.192 113.600 0.197
202209 0.381 116.400 0.382
202212 0.062 115.900 0.062
202303 0.683 117.300 0.680
202306 0.073 116.400 0.073
202309 0.421 117.400 0.418
202312 0.356 116.700 0.356

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab A/S  (NAS:GMAB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Genmab A/S Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (Genmab A/S) Business Description

Industry
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (Genmab A/S) Headlines

From GuruFocus